Melvin Berger

7.5k total citations · 1 hit paper
95 papers, 5.5k citations indexed

About

Melvin Berger is a scholar working on Immunology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Melvin Berger has authored 95 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Immunology, 29 papers in Hematology and 22 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Melvin Berger's work include Immunodeficiency and Autoimmune Disorders (37 papers), Platelet Disorders and Treatments (17 papers) and Neonatal Respiratory Health Research (16 papers). Melvin Berger is often cited by papers focused on Immunodeficiency and Autoimmune Disorders (37 papers), Platelet Disorders and Treatments (17 papers) and Neonatal Respiratory Health Research (16 papers). Melvin Berger collaborates with scholars based in United States, Switzerland and Canada. Melvin Berger's co-authors include Michael W. Konstan, James F. Chmiel, Tracey L. Bonfield, Aicha Saadane, Peter Kießling, Thomas A. Fleisher, R. Michael Blaese, Craig A. Mullen, Lauren A. Chang and W. French Anderson and has published in prestigious journals such as Science, New England Journal of Medicine and JAMA.

In The Last Decade

Melvin Berger

95 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

T Lymphocyte-Directed Gene Therapy for ADA ⁻ SCID: Initial Trial Results After 4 Years

1995 983 citations Melvin Berger et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Melvin Berger United States	40	2.2k	1.5k	1.5k	1.4k	1.2k	95	5.5k
Morton J. Cowan United States	42	2.4k 1.1×	1.2k 0.8×	777 0.5×	1.1k 0.8×	1.4k 1.2×	204	5.9k
Shigeaki Nonoyama Japan	45	5.9k 2.7×	1.9k 1.3×	1.3k 0.9×	2.0k 1.4×	1.1k 1.0×	186	9.3k
Alan D. Schreiber United States	50	2.9k 1.4×	819 0.5×	579 0.4×	2.7k 2.0×	1.7k 1.5×	140	8.4k
Asghar Aghamohammadi Iran	42	5.6k 2.6×	2.4k 1.6×	1.4k 0.9×	669 0.5×	968 0.8×	367	7.4k
Hendrik Schulze‐Koops Germany	48	3.5k 1.6×	511 0.3×	1.3k 0.9×	1.7k 1.2×	1.6k 1.4×	285	9.2k
Robertson Parkman United States	44	3.1k 1.4×	1.0k 0.7×	474 0.3×	1.3k 1.0×	2.7k 2.3×	169	6.8k
Peter G. Middleton United Kingdom	36	1.1k 0.5×	479 0.3×	1.5k 1.0×	880 0.6×	934 0.8×	141	4.2k
Lars Kjeldsen Denmark	51	2.4k 1.1×	798 0.5×	884 0.6×	3.4k 2.5×	2.8k 2.4×	133	9.7k
Bernd H. Belohradsky Germany	38	2.4k 1.1×	1.2k 0.8×	515 0.3×	1.4k 1.0×	359 0.3×	98	5.1k
Thomas A. Fleisher United States	34	2.2k 1.0×	1.2k 0.8×	296 0.2×	1.8k 1.3×	738 0.6×	55	5.5k

Countries citing papers authored by Melvin Berger

Since Specialization

Citations

This map shows the geographic impact of Melvin Berger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melvin Berger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melvin Berger more than expected).

Fields of papers citing papers by Melvin Berger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melvin Berger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melvin Berger. The network helps show where Melvin Berger may publish in the future.

Co-authorship network of co-authors of Melvin Berger

This figure shows the co-authorship network connecting the top 25 collaborators of Melvin Berger. A scholar is included among the top collaborators of Melvin Berger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melvin Berger. Melvin Berger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Berger, Melvin, et al.. (2017). Primary immune deficiency diseases as unrecognized causes of chronic respiratory disease. Respiratory Medicine. 132. 181–188. 39 indexed citations

Stein, Mark R., et al.. (2011). Safety and efficacy of Home-Based Subcutaneous Immunoglobulin G in Elderly Patients with Primary Immunodeficiency Diseases. Postgraduate Medicine. 123(5). 186–193. 22 indexed citations

Berger, Melvin. (2011). Choices in IgG replacement therapy for primary immune deficiency diseases. Current Opinion in Allergy and Clinical Immunology. 11(6). 532–538. 61 indexed citations

Saadane, Aicha, Jean Eastman, Melvin Berger, & Tracey L. Bonfield. (2011). Parthenolide inhibits ERK and AP-1 which are dysregulated and contribute to excessive IL-8 expression and secretion in cystic fibrosis cells. Journal of Inflammation. 8(1). 26–26. 33 indexed citations

Berger, Melvin, Mikhail Rojavin, Peter Kießling, & O. Zenker. (2011). Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clinical Immunology. 139(2). 133–141. 80 indexed citations

Berger, Melvin, et al.. (2009). Efficacy, Pharmacokinetics, Safety, and Tolerability of Flebogamma® 10% DIF, a High-Purity Human Intravenous Immunoglobulin, in Primary Immunodeficiency. Journal of Clinical Immunology. 30(2). 321–329. 25 indexed citations

Berger, Melvin. (2008). Subcutaneous Administration of IgG. Immunology and Allergy Clinics of North America. 28(4). 779–802. 91 indexed citations

Berger, Melvin, et al.. (2007). A Multicenter, Prospective, Open Label, Historically Controlled Clinical Trial to Evaluate Efficacy and Safety in Primary Immunodeficiency Diseases (PID) Patients of Flebogamma® 5% DIF, the Next Generation of Flebogamma®. Journal of Clinical Immunology. 27(6). 628–633. 33 indexed citations

Berger, Melvin, et al.. (2005). Subcutaneous Immunoglobulin-G Replacement Therapy with Preparations Currently Available in the United States for Intravenous or Intramuscular Use: Reasons and Regimens. Allergy Asthma and Clinical Immunology. 1(3). 120–30. 16 indexed citations

10.

Redline, Susan, Emma K. Larkin, Carolyn M. Kercsmar, Melvin Berger, & Laura A. Siminoff. (2003). Development and validation of school-based asthma and allergy screening instruments for parents and students. Annals of Allergy Asthma & Immunology. 90(5). 516–528. 35 indexed citations

11.

Chmiel, James F., et al.. (2002). Prolonged Inflammatory Response to Acute Pseudomonas Challenge in Interleukin-10 Knockout Mice. American Journal of Respiratory and Critical Care Medicine. 165(8). 1176–1181. 66 indexed citations

12.

Šoltýs, Jindřich, Tracey L. Bonfield, James F. Chmiel, & Melvin Berger. (2002). Functional IL-10 Deficiency in the Lung of Cystic Fibrosis ( cftr −/−) and IL-10 Knockout Mice Causes Increased Expression and Function of B7 Costimulatory Molecules on Alveolar Macrophages. The Journal of Immunology. 168(4). 1903–1910. 60 indexed citations

13.

Berger, Melvin. (2002). A history of immune globulin therapy, from the harvard crash program to monoclonal antibodies. Current Allergy and Asthma Reports. 2(5). 368–378. 39 indexed citations

14.

Neufert, Clemens, Rish K. Pai, Erika H. Noss, et al.. (2001). Mycobacterium tuberculosis 19-kDa Lipoprotein Promotes Neutrophil Activation. The Journal of Immunology. 167(3). 1542–1549. 75 indexed citations

15.

Chmiel, James F., Michael W. Konstan, Jay B. Hilliard, et al.. (1999). IL-10 Attenuates Excessive Inflammation in Chronic Pseudomonas Infection in Mice. American Journal of Respiratory and Critical Care Medicine. 160(6). 2040–2047. 101 indexed citations

16.

Yoshida, Yuichi, Kefei Kang, Melvin Berger, et al.. (1998). Monocyte Induction of IL-10 and Down-Regulation of IL-12 by iC3b Deposited in Ultraviolet-Exposed Human Skin. The Journal of Immunology. 161(11). 5873–5879. 63 indexed citations

17.

Konstan, Michael W. & Melvin Berger. (1997). Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology. Pediatric Pulmonology. 24(2). 137–142. 256 indexed citations

18.

Clapp, D. Wade, et al.. (1989). Use of intravenously administered immune globulin to prevent nosocomial sepsis in low birth weight infants: Report of a pilot study. The Journal of Pediatrics. 115(6). 973–978. 68 indexed citations

19.

Levy, Yael, Michael S. Hershfield, Cristina Fernández‐Mejía, et al.. (1988). Adenosine deaminase deficiency with late onset of recurrent infections: Response to treatment with polyethylene glycol-modified adenosine deaminase. The Journal of Pediatrics. 113(2). 312–317. 158 indexed citations

20.

Berger, Melvin. (1987). Immunoglobulin G subclass determination in diagnosis and management of antibody deficiency syndromes. The Journal of Pediatrics. 110(2). 325–328. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact